Overview

* Voyager Q2 collaboration revenue falls sharply yr/yr, driven by Neurocrine agreements

* Co extends cash runway into 2028, supporting multiple clinical data read-outs

* Voyager adds APOE program to Alzheimer's pipeline, expanding franchise

Outlook

* Voyager expects cash runway to extend into 2028

Result Drivers

* NEUROCRINE PARTNERSHIP - Collaboration revenue decrease due to lower revenue recognized under Neurocrine collaboration

* CASH RUNWAY - Co extended cash runway into 2028 through restructuring and cost savings, enabling focus on clinical data

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $5.20

Collabor mln

ation

Revenue

Q2 EPS -$0.57

Q2 Net -$33.38

Income mln

Q2 Basic -$0.57

EPS

Q2 -$36.62

Operatin mln

g Income

Q2 -$33.37

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Voyager Therapeutics Inc ( VYGR ) is $15.00, about 77.5% above its August 5 closing price of $3.38

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)